Actively Recruiting
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
Led by Samsung Medical Center · Updated on 2021-05-11
700
Participants Needed
1
Research Sites
487 weeks
Total Duration
On this page
Sponsors
S
Samsung Medical Center
Lead Sponsor
G
Guardant Health, Inc.
Collaborating Sponsor
AI-Summary
What this Trial Is About
The aim of the study is to evaluate whether peripheral circulating cell-free tumor DNA (cfDNA) can aid screening of recurrence after complete resection of early stage non-small cell lung cancer.
CONDITIONS
Official Title
Cell Free DNA for the Diagnosis and Treatment in Early NSCLC
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Signed informed consent form
- Diagnosed or suspected non-small cell lung cancer before surgery
- Pathologically confirmed non-small cell lung cancer after surgery
- Clinical stage I to IIIA by AJCC 7th staging system
You will not qualify if you...
- Received chemotherapy or radiotherapy for non-small cell lung cancer
- Diagnosed with any cancer other than skin, thyroid, or uterine cervix cancer within 3 years before enrollment
- Recurrent lung cancer
- Clinical stage IIIB or IV by AJCC 7th staging system
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Samsung Medical Center
Seoul, South Korea, 06351
Actively Recruiting
Research Team
J
Jhingook Kim, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here